Bays, Harold E.
Rosenson, Robert S.
Baccara-Dinet, Marie T.
Louie, Michael J.
Thompson, Desmond
Hovingh, G. Kees
Funding for this research was provided by:
Sanofi
Regeneron Pharmaceuticals
Article History
First Online: 7 April 2018
Change Date: 27 April 2018
Change Type: Correction
Change Details: The original version of this article unfortunately contained a mistake in the Discussion section.
Compliance with Ethical Standards
:
: Harold E. Bays has served as a consultant and/or speaker to Alnylam, Amarin, Amgen, AstraZeneca, Eisai, Eli Lilly, Merck, Novartis, NovoNordisk, Regeneron Pharmaceuticals, Inc., Sanofi, and Takeda and has received research grants from Amarin, Amgen, Ardea, Arisaph, Catabasis, Cymabay, Eisai, Elcelyx, Eli Lilly, Esperion, Hanmi, Hisun, F. Hoffman LaRoche, Home Access, Janssen, Johnson and Johnson, Merck, Necktar, Novartis, Novo Nordisk, Omthera, Orexigen, Pfizer, Pronova, Regeneron Pharmaceuticals, Inc., Sanofi, Takeda, TIMI, VIVUS, and Wpu Pharmaceuticals.Robert S. Rosenson has received research grants from Amgen, AstraZeneca, Esperion, Medicines Company, Regeneron Pharmaceuticals, Inc., and Sanofi; has served as a consultant/on advisory boards for Amgen, Akcea, AstraZeneca, CVS Caremark, Easy Vitals, Eli Lilly, and Sanofi; and receives royalties from UpToDate.Marie T. Baccara-Dinet is an employee and stockholder of Sanofi.Michael J. Louie is an employee and stockholder of Regeneron Pharmaceuticals, Inc.Desmond Thompson is a consultant to Medical Affairs at Regeneron Pharmaceuticals, Inc.G. Kees Hovingh’s institution has received payment for conducting clinical trials from Sanofi, Regeneron Pharmaceuticals, Inc., Amgen, Pfizer, Kowa, Genzyme, Ionis Pharmaceuticals, Roche, Eli Lilly, Aegerion, Synageva, and AstraZeneca and for lectures and/or advisory panel participation from Amgen, Sanofi, Pfizer, and Roche.